CKD Bio Corp.

063160KOSPIPharmaceuticals

CKD Bio Corp. (063160, KOSPI) reported KRW 160bn revenue in 2025.

Reported financials

Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.

YearRevenueOperating profitNet profitAssetsEquityBasis
2021142-11-7299161Consolidated
2022156-15-17313148Consolidated
2023160-20-24294123Separate
2024172119284131Separate
20251604-3300127Separate

Ratios, year by year

Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.

YearOperating marginNet marginEquity / assetsReturn on equity
2021-8%-4.6%54.1%-4.1%
2022-9.5%-10.7%47.3%-11.3%
2023-12.6%-15.1%41.9%-19.7%
20246.4%5.1%46.1%6.6%
20252.3%-1.8%42.4%-2.3%

Revenue moved 12.5% between 2021 and 2025.

Net profit was negative in the 1 most recent year on file. Counted from the 5 years in which the company filed a net-profit line — a year with no filing is skipped, not read as a loss.

These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.

Market size

Market capitalisationKRW 73bn
Close priceKRW 13,280
Listed shares5,485,962
Price as of20260909

Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.

When it was founded

The incorporation date on the company's registration record, as filed with Korea's Financial Supervisory Service. This is when the company was legally formed — not when it first listed, and not when the business it grew out of began trading.

Incorporated

Who runs it

Registered representative directors — in Korea this is the office a CEO holds. Filed with the Financial Supervisory Service (DART). A Korean company can register more than one, and the title beside each name is the rank they carry inside the company.

NameTitleBoard seatYears in post
Park Wan-gap (박완갑)Representative Director (CEO), Senior Managing DirectorInside director1 year

Roman spellings are ours, converted from the Korean filing. The person may spell their own name differently in English. The Korean name in brackets is what was filed.

Workforce — a side measure, not the main one

Employees (2025)533
Women103 (19.3%)
Average tenure10.2 years
Annual pay, menKRW 71,770,000
Annual pay, womenKRW 57,329,000
Pay ratio, women to men79.9%

Other companies in Pharmaceuticals

181 listed companies file under this classification. Showing 12.

See the whole Pharmaceuticals list →